ModeX Therapeutics

ModeX Therapeutics is a private, preclinical-stage biotech focused on creating multispecific biologic drugs using its proprietary MSTAR and Nanoparticle Vaccine platforms. The company, a spin-out/affiliate of OPKO Health, is led by a highly experienced team with deep roots in academia, government (NIH), and industry. Its strategy centers on developing single-molecule therapies that engage multiple disease targets simultaneously, aiming to improve efficacy and overcome limitations of traditional monoclonal antibodies in complex diseases like oncology and virology.

MSTAR (Multispecific Therapeutics via Advanced Reengineering) platform for multispecific antibodies; Nanoparticle Vaccine platform for infectious diseases.

ModeX competes in the crowded multispecific antibody space against companies like Genmab, Regeneron, and numerous biotechs, and in novel vaccines against Moderna, Novavax, and GSK. Its differentiation lies in its specific protein engineering and nanoparticle design expertise and its leadership's deep translational experience from the NIH.